The Psychedelic Approval Odds Sheet

Name: Psychedelic Approval Odds Sheet
Creator: OOTWOracle

The Oracle's current odds on the 12 nearest-resolving open questions in psychedelic medicine — regenerated daily from live signals. Print it, share it, check back when they resolve.

Question	Odds
Scientists will publicly push back on 'mushrooms rewire the brain' headlines research · resolves 2026-09-04	67%
MindMed reveals the real reason behind its mysterious stock surge capital-markets · resolves 2026-09-05	60%
Experts will question a ketamine therapy pilot study's methods within weeks research · resolves 2026-09-08	66%
COMPASS Pathways stock unlikely to spike or crash before September 10 markets · resolves 2026-09-10	70%
Scientists publish major new findings on exactly how psilocybin works in the brain research · resolves 2026-09-11	74%
Brain science on psychedelics will outrun human clinical proof in 2026 research · resolves 2026-09-12	70%
The FDA will not approve MDMA as a PTSD treatment before September 2026 regulatory · resolves 2026-09-13	78%
A major veterans group will back psychedelic medicine access within 6 weeks legislation · resolves 2026-09-13	63%
MindMed will make a major company announcement within six weeks capital-markets · resolves 2026-09-14	64%
Congress won't hold a full floor vote on any psychedelic-focused bill before fall 2026 legislation · resolves 2026-09-15	80%
COMPASS Pathways stock price likely stays flat through mid-September 2026 markets · resolves 2026-09-15	74%
Major news outlet will question ibogaine's heart risks or political push cultural · resolves 2026-09-15	70%

Want the updated sheet every morning?

Daily signal + 5 fresh predictions + the honest track record. Free.

Subscribe free →

Methodology: odds are the Oracle's calibrated confidence, produced by a multi-agent simulation over ~150 daily signals (PubMed, ClinicalTrials.gov, Congress.gov, market data, press). Every question carries a falsifiable resolution rule and is scored publicly — see the track record.